Climb Bio, Inc. (NASDAQ:CLYM – Get Free Report) hit a new 52-week high on Monday . The company traded as high as $14.11 and last traded at $13.8550, with a volume of 196538 shares traded. The stock had previously closed at $12.90.
Wall Street Analysts Forecast Growth
A number of analysts have commented on CLYM shares. Chardan Capital began coverage on Climb Bio in a report on Tuesday, May 5th. They issued a “buy” rating and a $22.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Climb Bio in a report on Wednesday, June 24th. B. Riley Financial assumed coverage on Climb Bio in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price objective on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Climb Bio in a report on Monday, April 20th. Finally, Robert W. Baird set a $21.00 target price on Climb Bio in a research report on Wednesday, May 6th. Three analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Climb Bio currently has a consensus rating of “Buy” and an average target price of $21.73.
View Our Latest Report on Climb Bio
Climb Bio Stock Up 10.7%
Climb Bio (NASDAQ:CLYM – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.06. Equities research analysts expect that Climb Bio, Inc. will post -0.87 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the company. MPM Bioimpact LLC bought a new stake in shares of Climb Bio during the 4th quarter valued at about $10,686,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Climb Bio by 265.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,923,639 shares of the company’s stock worth $7,695,000 after purchasing an additional 1,396,722 shares during the period. ADAR1 Capital Management LLC boosted its holdings in shares of Climb Bio by 972.8% in the fourth quarter. ADAR1 Capital Management LLC now owns 1,432,475 shares of the company’s stock worth $5,730,000 after buying an additional 1,298,945 shares during the last quarter. Sphera Funds Management LTD. boosted its holdings in shares of Climb Bio by 114.4% in the fourth quarter. Sphera Funds Management LTD. now owns 932,247 shares of the company’s stock worth $3,729,000 after buying an additional 497,410 shares during the last quarter. Finally, Peapod Lane Capital LLC grew its position in Climb Bio by 0.7% during the fourth quarter. Peapod Lane Capital LLC now owns 565,992 shares of the company’s stock valued at $2,264,000 after buying an additional 4,126 shares during the period. Institutional investors own 69.76% of the company’s stock.
About Climb Bio
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
Read More
- Five stocks we like better than Climb Bio
- AI Is Selling Off, But These 5 Stocks Could Benefit Next
- These 3 Stocks Offer Investors Exposure to the Functional Beverage Boom
- Alcoa’s $4.1 Billion South32 Deal: Opportunity Behind the 9% Drop
- 3 High-Yield Dividend Stocks With Real Capital Gains Potential in 2026
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
